Source disclosure: February 25, 2026
TSUMURA & CO. [4540.T]
TOKYO — Tsumura & Co., a leading manufacturer of traditional Chinese and Kampo medicines, announced on Saturday that it has entered into an agreement to acquire shares from Yōmeishu Seizo Co., Ltd., marking a significant step towards consolidating its shareholding structure. The company also set a delisting date as part of this strategic move aimed at enhancing operational efficiency and focusing on long-term growth.
Under the terms of the agreement, Tsumura & Co. will proceed with a share consolidation plan designed to streamline ownership and governance structures. This consolidation is expected to strengthen the company's position within the healthcare industry by allowing for more focused investment in research and development activities, particularly in personalized health care solutions tailored to individual needs. The consolidation process is scheduled to be completed by February 25, 2026, following which Yōmeishu Seizo Co., Ltd. will be delisted from the stock exchange.
The overarching vision guiding these actions is encapsulated in the "TSUMURA VISION 'Cho-WA' 2031," which aims to provide evidence-based products and services that cater to various life stages, symptoms, genetic predispositions, and living environments. By doing so, Tsumura & Co. seeks to contribute to the well-being of individuals through targeted interventions such as diagnosing and addressing conditions defined under the concept of "pre-disease" (). Additionally, the company plans to foster a corporate culture where dialogue empowers employees to maximize their potential, thereby driving innovation in the field of traditional medicine and establishing itself as a trusted entity both domestically and internationally.
AI-translated content. 🟢 Confidence: High See terms • Original filing